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Abstract
Background: In order to harmonize results for the detection and quantification of Plasmodium
falciparum DNA by nucleic acid amplification technique (NAT)-based assays, a World Health
Organization (WHO) collaborative study was performed, evaluating a series of candidate standard
preparations.
Methods: Fourteen laboratories from 10 different countries participated in the collaborative
study. Four candidate preparations based upon blood samples parasitaemic for P. falciparum were
evaluated in the study. Sample AA was lyophilized, whilst samples BB, CC and DD were liquid/
frozen preparations. The candidate standards were tested by each laboratory at a range of dilutions
in four independent assays, using both qualitative and quantitative NAT-based assays. The results
were collated and analysed statistically.
Results: Twenty sets of data were returned from the participating laboratories and used to
determine the mean P. falciparum DNA content for each sample. The mean log10 "equivalents"/ml
were 8.51 for sample AA, 8.45 for sample BB, 8.35 for sample CC, and 5.51 for sample DD. The
freeze-dried preparation AA, was examined by accelerated thermal degradation studies and found
to be highly stable.
Conclusion: On the basis of the collaborative study, the freeze-dried material, AA (NIBSC code
No. 04/176) was established as the 1st WHO International Standard for P. falciparum DNA NAT-
based assays and has been assigned a potency of 109 International Units (IU) per ml. Each vial
contains 5 × 108 IU, equivalent to 0.5 ml of material after reconstitution.
Background
Each year there are an estimated 300 million acute cases
of malaria worldwide, accounting for more than one mil-
lion deaths annually [1]. In humans, malaria is caused by
infection with five species of Plasmodium (Plasmodium fal-
ciparum, Plasmodium malariae, Plasmodium ovale, Plasmo-
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dium vivax and  Plasmodium knowlesi).  Plasmodium
falciparum is associated with the greatest morbidity and
mortality, accounting for approximately 95% of deaths
due to malaria [2]. Although most of these cases are found
in endemic tropical regions of Africa, Asia, Central and
South America, cases of imported malaria are reported in
non-endemic areas. In Europe it has been estimated that
there are in excess of 10,000 cases of imported malaria per
year, with around 2,000 cases being recorded annually in
the UK alone [3,4]. Estimates by the Centers for Disease
Control and Prevention (United States) have indicated
that there were approximately 1,528 cases, including
seven fatal cases, of imported malaria in the United States
in 2005, largely due to travellers, immigrants and service-
men returning from malaria endemic regions [5]. Transfu-
sion transmitted cases of malaria can also occur, by the
use of contaminated blood, and may result in significant
disease or even death in the recipients, particularly when
P. falciparum is the causative agent [6].
Malaria diagnosis has relied upon microscopic analysis of
Wright's or Wright-Giemsa stained blood smears to detect
infection and determine parasite loads [7]. Slide interpre-
tation requires considerable expertise and is difficult to
standardize, particularly at low levels of parasitaemia or
where mixed species infections occur [8,9]. Nucleic acid
amplification technique (NAT)-based assays, such as PCR
are becoming increasingly employed in the diagnosis of
malaria [10,11]. Studies have shown that PCR can
improve sensitivity and species discrimination, when
compared to either microscopy or serological methods
[12]. Although numerous PCR methods have been devel-
oped for the laboratory diagnosis and clinical manage-
ment of malaria, the reported sensitivities of these assays
vary widely. These differences may be a result of intrinsic
variability in assay sensitivity or a consequence of calibra-
tion using different reference reagents, which are poorly
standardized. In terms of quality assurance, it is of con-
cern that variability in the implementation of assays
between laboratories could give different results for the
same patient sample.
In the last ten years, a number of International Standards
have been developed by the World Health Organization
(WHO) for NAT-based assays. The first was established in
1997 for hepatitis C virus (HCV) RNA [13]. This standard
was pivotal in the introduction of HCV RNA NAT screen-
ing of blood and plasma donations, used in transfusion
and the manufacture of plasma derived medicinal prod-
ucts, where previously there had been transmissions of
HCV. Further standards have been established for hepati-
tis B virus (HBV) DNA, HIV-1 RNA, parvovirus B19 DNA,
hepatitis A virus (HAV) RNA [14-17]. The standards have
allowed the development of regulatory requirements for
the detection of these blood borne viruses in plasma, by
setting commonly recognized thresholds and limits of
detection. The standards have been used in the calibration
of secondary standards and working reagents, and have
been used in the validation of assays for both the qualita-
tive and quantitative NAT-based techniques. These blood-
borne virus standards have also found use in the clinical
setting, both for diagnosis and for monitoring viral loads
in response to antiviral therapy. Moreover, results in a
number of commercially available assays for blood borne
viruses are expressed in terms of WHO International Units
associated with the respective standards.
This paper describes a collaborative study to evaluate four
candidate standards for their suitability for use as a WHO
International Standard for P. falciparum DNA for use in
NAT-based assays. The value of such a standard will be to
ensure consistent assay implementation between labora-
tories; allow inter-laboratory comparisons; provide mate-
rials for assay validation; and in particular to generate
secondary standards to monitor routine assay use. The
need for such a material was recognized by the WHO
Expert Committee on Biological Standardization (ECBS)
in 2004.
Methods
Candidate standards
Four candidate standards were included in this study.
Sample AA was a freeze-dried preparation of blood,
obtained from a patient infected with P. falciparum follow-
ing an exchange transfusion. Local Research Ethical Com-
mittee approval was obtained at the London Hospital for
Tropical Diseases for the collection and subsequent use of
this sample. The blood used to prepare sample AA, was
determined to have an overall parasitaemia of approxi-
mately 9.8% by light microscopy. Sample AA was stored
at -70°C until lyophilization. The conditions for lyophili-
zation were as previously described [13,14]. Lyophilized
vials of AA have been stored at -20°C with constant tem-
perature monitoring, at the National Institute for Biologi-
cal Standards and Control (NIBSC). Sample BB was a
liquid preparation, of in vitro cultured P. falciparum (3D7
strain) prepared in leucodepleted blood, with a parasitae-
mia of approximately 10%. Sample CC was a liquid prep-
aration of approximately 6.9% parasitaemia of P.
falciparum infected blood, obtained from the same patient
as sample AA. Sample DD was a 1:1000 dilution of sam-
ple CC prepared in leucodepleted blood. Samples BB, CC
and DD were dispensed in 0.5 ml volumes and stored as
liquid/frozen preparations at -70°C. All samples tested
negative by PCR for the following viral markers: HBV
DNA, HCV RNA, HAV RNA, HIV-1 RNA and parvovirus
B19 DNA.Malaria Journal 2008, 7:139 http://www.malariajournal.com/content/7/1/139
Page 3 of 9
(page number not for citation purposes)
Design of the study
Fourteen laboratories participated in the collaborative
study. Laboratories were sent four vials of each of the can-
didate standards. The participants were requested to store
samples at or below -70°C until analysis. The lyophilized
preparation (AA) was reconstituted using 0.5 ml of nucle-
ase-free deionized water immediately prior to analysis,
with gentle agitation for 20 minutes to fully dissolve the
contents. The liquid preparations (BB, CC and DD) were
to be thawed quickly before use. Participants were
requested to test the panel of candidate standards in four
independent assays for P. falciparum DNA, using fresh
vials of the four candidates for each assay run. In the case
of qualitative assays, serial dilutions of the samples were
analysed in four independent assays. In the first qualita-
tive assay, ten-fold dilutions were performed to determine
the end point for the detection of P. falciparum DNA. In
each of the subsequent three assays, a minimum of two
half-log10 (i.e. 1:3.2) dilutions either side of the pre-deter-
mined end-point were assayed, and results reported as
positive or negative. Participants were requested to pre-
pare dilutions in the sample diluent normally used in
their assay system. In the case of quantitative assays for P.
falciparum DNA, results were used directly as returned by
laboratories, after correction for any dilutions made.
Statistical methods
The qualitative end-point assays were analyzed using the
Poisson model, as previously described for collaborative
studies for other NAT standards [13,15]. All estimates
were expressed as log10 PCR detectable units/ml. Overall
means were calculated as arithmetic means of the log10
estimates.
Stability studies
The lyophilized candidate standard (AA) was analysed for
its stability over time in accelerated thermal degradation
studies. Samples were incubated in temperature control-
led environments, withdrawn at specified times and ana-
lysed for P. falciparum DNA content as described below.
Following reconstitution, 200 μl volumes of sample for
AA were extracted using the MagNA Pure LC instrument
with software version 4.0 (Roche Applied Science, Man-
nheim, Germany). Samples were extracted using the DNA
Isolation Kit I (Roche Applied Science, Mannheim, Ger-
many) according to the manufacturer's instructions. Elu-
tion was performed with 100 μl of elution buffer. Real-
time PCRs were performed on the LightCycler 2.0 instru-
ment (Roche Applied Science, Mannheim, Germany). An
in-house TaqMan assay was performed using primers
selected from the most conserved regions of the 18S ribos-
omal RNA (rRNA) gene. The primer sequences were as fol-
lows: forward primer, 5' CAG ATG TCA GAG GTC AAA
TTC TAA GAT T 3'; reverse primer, 5' TCC CTT AAC TTT
CGT TCT TGA TTA ATG 3'. The sequence of the fluoro-
genic hydrolysis probe was as follows: 5' (FAM) CTG GAG
ACG GAC TAC TGC GAA AGC ATT TG (TAMRA) 3'.
Amplification reactions were performed using the Light-
Cycler FastStart DNA Master Hybprobe kit (Roche
Applied Science, Mannheim, Germany). The amplifica-
tion conditions were as follows: 95°C for 10 min, then 45
cycles of the following sequential steps: 95 °C for 15s,
60°C for 1 min. Fluorescence data was collected during
the combined annealing/extension step and detected at
530 nm. A standard curve was generated using serial ten-
fold dilutions of a sample with a concentration of
180,000 parasites per μl, as determined by Giemsa-
stained thin film microscopy by a proficient operator,
with independent confirmation.
Results
Data returned and data analysis
Fourteen laboratories from 10 countries, returned results
from four assays for each of the four separate prepara-
tions. The participants included parasitology laboratories
from tropical medicine institutes, universities, hospitals,
quality control laboratories, manufacturers of diagnostic
kits and other laboratories. The majority of assays used by
the participating laboratories were ones developed in-
house, although participants returned results from com-
mercial assays. Throughout this study, a code number has
been allocated at random for each laboratory and does
not necessarily represent the order of the participants
described in Table 1. The types of assays used by partici-
pants are listed in Table 2.
Participating laboratories were requested to test the sam-
ples in qualitative or quantitative format in order to deter-
mine the P. falciparum DNA content for each of the four
candidate standards. The majority of laboratories pro-
vided data from qualitative end-point dilution assays.
These laboratories reported the number of samples posi-
tive out of the number tested at various dilutions. These
were treated as a dilution series and used to provide a sin-
gle estimate of "PCR-detectable units/ml" in the undi-
luted sample using the method of maximum likelihood
for "dilution assays" as described for the analysis of other
NAT standards [13,15]. The model assumes that the prob-
ability of a positive result at a given dilution follows a
Poisson distribution (with the mean given by the expected
number of "copies" in the sample tested, and that a single
copy will lead to a positive result). Calculations were car-
ried out using the statistical package GLIM [13,15].
Where a laboratory marked a result as uncertain or +/-, it
was treated as negative. Where a laboratory performed
more than one assay method, the results were analyzed
separately, treated as if from separate laboratories, and
coded as for example as laboratories 1A and 1B. Labora-
tory 1B did not continue the dilution series for sample AAMalaria Journal 2008, 7:139 http://www.malariajournal.com/content/7/1/139
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until negative responses were observed. It was therefore
not possible to calculate an estimate of units/ml for this
sample (see below). For assays 2–4, Laboratory 9 only
tested single log dilutions to the endpoint rather than
half-log dilutions at the supposed end point. It was still
possible to determine estimates of detectable units/ml,
but they may be less precise than for other laboratories.
Laboratory 10 (10A & 10B) had some positives at very
high dilutions. Because the Poisson model could not be
fitted with these results, they were excluded as potential
false positives. Laboratory 11 (11A & 11B) reported "dilu-
tions not well executed" for assay 2, which was therefore
excluded. It was not possible to obtain an estimate of
detectable units/ml for sample CC for 11A, as all results
were positive. Some of the remaining results from 11B
were also inconsistent. Laboratory 14B had some incon-
sistent negatives at 10-1 and 10-2 for sample DD in assay 2,
which were excluded.
Table 1: Collaborative study participants
Name Affiliation
Dr A Calderaro University of Parma, Parma, Italy
Prof. PL Chiodini Hospital for Tropical Diseases, London, UK
Dr C Defer EFS Nord de France, Lille, France
Dr I Felger Swiss Tropical Institute, Basel, Switzerland
Dr KC Kain Center for Travel and Tropical Medicine, Toronto, Canada
Prof. S Krishna St. George's Hospital, London, UK
Dr R Lee Institute of Clinical Pathology & Medical Research, Westmead, Australia
Mr DJ Padley NIBSC, South Mimms, UK
Dr F Perandin University of Brescia, Brescia, Italy
Dr G Pisani Istituto Superiore di Sanità, Rome, Italy
Dr T Ruckes Qiagen GmbH, Hamburg, Germany
Dr AJ da Silva Centers for Disease Control and Prevention, Atlanta, USA
Dr S Salueda Banc de Sang I Teixits, Barcelona, Spain
Prof. R Sauerwein Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Table 2: Assay methodologies used by study participants
Lab No. Nucleic Acid Extraction Nucleic Acid Amplification Sequence Targeted
1A QIAamp DNA Mini Blood Kit Qiagen Taq DNA polymerase Small subunit rRNAa
1B QIAamp DNA Mini Blood Kit TaqMan® universal Master MIX Conserved ATS domain of var genes
2A QIAamp DNA Blood kit Eppendorf Master Mix 2.5 × kit, gel based assay 18S rRNAb
2B QIAamp DNA Blood kit QuantiTectProbe PCR Kit, real-time PCR 18S rRNAb
3A MagNA Pure LC Total Nucleic Acid Isolation 
Kit
LightCycler Fast Start DNA Master 
SYBRGreen I
18S rRNA
3B MagNA Pure LC Total Nucleic Acid Isolation 
Kit
RealArt™ Malaria LC PCR Kit 18S rRNA
4 QIAamp DNA Blood Mini Kit MBI Taq DNA polymerase Small subunit rRNA genea
5 Boom et al., 1990 [20] RNA T7 Polymerase, AMV-RT, RNAse H, 
bioMerieux
18S rRNAc
6 MagNA Pure LC DNA Isolation Kit I LightCycler FastStart DNA MasterPLUS 
Hybprobe
18S rRNA
7 QIAamp DNA Mini Kit Taqman 2 × Universal PCR Mastermix β-tubulind
8 QIAamp DNA Mini Kit TaqMan® Universal Master Mix 18S rRNAb
9 QIAamp DNA Mini Blood Kit N/A 18S rRNA
10A QIAamp DNA Mini Blood Kit Bioline Taq Polymerase 18S rRNAa
10B QIAamp DNA Mini Blood Kit Fast Start DNA Sybr Green Kit 18S rRNA
11A Roche High Pure PCR Template Preparation 
Kit
Applera Taq Polymerase, Applied Biosystems 18S rRNAe
11B Roche High Pure PCR Template Preparation 
Kit
2 × Taqman Universal 18S rRNAa
12 QIAamp DNA Mini Blood Kit AmpliTaq Gold DNA Polymerase 18S rRNAa
13 QIAamp DNA Blood/Mini Kit artus Malaria PCR Kit 18S rRNA
14 High Pure PCR Template Preparation Kit Applied Biosystems Taq Polymerase 18S rRNAe
Assays performed according to the following published methods a[18,19], b [extraction method only, [20]], c[21], d[22], e[23], For other assays there 
were either no previously published methods or the information was not disclosedMalaria Journal 2008, 7:139 http://www.malariajournal.com/content/7/1/139
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Two laboratories provided quantitative results. Labora-
tory 3B provided quantitative results using a commercial
kit (Artus RealArt Malaria LC PCR kit, Qiagen, Hamburg,
Germany) for a range of dilutions for each sample. The
results were quoted as copies/μl. Laboratory 5, provided
results from an in-house quantitative assay, giving results
as a mean log10 Par/ml based on two sets of triplicate
determinations for each sample.
Estimates of PCR-detectable units/ml
The estimated log10 PCR-detectable units/ml for each of
the four candidate standards from the qualitative end-
point assays are shown in histogram form in Figure 1 and
in Table 3. Each box represents the estimate from one lab-
oratory, and is labeled with the laboratory code number.
The overall means, range and between laboratory stand-
ard deviations are shown in Table 4. The agreement
between laboratories is similar to that observed in the col-
laborative study to establish the 1st International Standard
for HCV RNA for NAT-based assays [13]. The quantitative
results from laboratories 3B and 5 are shown in Table 5.
For laboratory 3B, the results are based on the neat and 1
in 10 dilutions only, as the results did not appear linear
for dilutions beyond this. Results were expressed as "cop-
ies/ul". For laboratory 5, results were expressed as "Par/
ml". The estimates from laboratory 3B are much higher
than the results from the qualitative assays, particularly
for samples AA, BB and CC. For laboratory 5, the estimates
for samples AA, CC and DD are much lower than those
from the qualitative assays. The estimate for sample BB is
of the same order as the qualitative assays, but 4 log10
higher than the equivalent estimates of AA and CC. This
may be due to the fact that this particular assay is amplify-
ing RNA and not DNA, compared to the other assays.
Samples AA, CC and DD were subject to multiple rounds
of freeze-thawing during their preparation, and due to cell
lysis, the labile nature of RNA and its susceptibility to deg-
radation by nucleases have resulted in loss of potency of
these preparations when RNA levels are examined. Sam-
ple BB only underwent a single freeze-thaw cycle before
dispatch to study participants and hence has a higher
potency in this particular assay for Laboratory 5. These
results emphasize that this candidate standard is not suit-
able for RNA assays.
Figure 2 shows the performance of the four candidate
standard preparations in a real-time TaqMan PCR assay
(as described in Stability Studies section of the Materials
and Methods), which further demonstrates mean esti-
mated PCR detectable units/ml values shown in Table 4.
Near identical crossing cycle (Ct) values are found for
samples AA, BB and CC, with sample DD generating a
much later Ct values reflecting the dilution of this mate-
rial when it was originally prepared. It should be noted
that sample AA was derived from blood from an exchange
transfusion that was determined to have an overall parasi-
taemia of approximately 9.8% which had been deter-
mined by light microscopy. Sample BB was a liquid
preparation of in vitro cultured P. falciparum (3D7 strain)
with a parasitaemia of approximately 10% was also eval-
uated in this study. The mean estimates of these two prep-
arations AA and BB are 8.51 and 8.45 log10 PCR
detectable units/ml respectively based upon the results of
the end point dilution assays, demonstrating that the
Table 3: Estimated PCR-detectable units/ml (log10) calculated 
from end-point dilution assays.
Lab Sample
AA BB CC DD
1A 8.51 8.12 7.96 5.82
1B - 8.87 9.26 6.23
2A 8.26 8.26 7.98 5.15
2B 8.14 7.90 7.98 5.12
3A 7.44 7.62 7.84 4.51
4 7.56 8.71 8.25 5.84
6 8.14 9.32 8.95 5.62
7 7.54 8.12 7.89 4.97
8 8.44 8.28 8.28 5.58
9 9.31 8.18 8.80 5.80
10A 9.41 9.23 8.99 5.73
10B 8.65 8.36 8.39 5.42
11A 8.46 8.44 - 5.17
11B 8.45 7.70 6.35 5.12
12 8.96 9.64 9.92 6.86
13 10.46 9.85 9.47 6.39
14A 8.62 7.79 8.00 5.07
14B 8.28 7.62 7.68 4.74
Mean 8.51 8.45 8.35 5.55
Table 4: Overall mean estimated PCR detectable units/ml (log10) 
from end-point assays
Sample N Mean Min Max Range SD
AA 17 8.51 7.44 10.46 3.01 0.74
BB 18 8.45 7.62 9.85 2.23 0.69
CC 17 8.35 6.35 9.92 3.57 0.83
DD 18 5.51 4.51 6.86 2.36 0.60
N – Number of laboratory estimates
SD – Standard Deviation of log10 estimates across laboratories
Table 5: Mean estimates from quantitative assays
Sample
AA BB CC DD
Lab 3B log10 copies/μl 9.93 9.34 10.20 3.48
Lab 5 log10 Par/ml 4.21 8.12 3.99 0.93Malaria Journal 2008, 7:139 http://www.malariajournal.com/content/7/1/139
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patient derived sample AA gives results that are commut-
able to the in vitro propagated sample derived from the
3D7 laboratory strain of P. falciparum.
Stability studies on candidate sample AA
The stability of sample AA was examined over time in
accelerated degradation studies. Samples were incubated
in temperature controlled environments, withdrawn at
specified times and tested for P. falciparum DNA content.
A baseline titre was determined by comparison to vials of
sample AA stored at -20°C (i.e. the long term storage tem-
perature for lyophilized standards). The overall geometric
means (log10) for the estimated parasites/ul were deter-
mined for the sample AA at each of the different incuba-
tion temperatures. This is displayed as the log10 drop
(Table 6). At the higher temperatures there is clearly some
degradation, with a drop of around 0.3 log10 after a year at
+20°C, and around 0.6 log10  at higher temperatures.
There was little observed loss at +4°C however, with an
apparent increase at 8 months, and a loss of 0.06 log10 at
12 months. This data is based on a limited number of vials
however, and these differences are within the expected
assay variability. If the Arrhenius model for accelerated
degradation [24,25] is applied to this data, a predicted
loss per year at -20°C of around 20%, or 0.1 log10 is
obtained. However this is not a precise estimate. This pre-
diction does not appear to be consistent with the observed
data for the sample stored at +4°C, which has not shown
degradation of the order of that predicted for the -20°C
sample. It is not clear whether the Arrhenius model,
which is based on a simple first order degradation process,
is appropriate for material of this type. Although there is
degradation at higher temperatures, there is little observed
degradation after 12 months at +4°C and this observed
stability is in line with that observed for the WHO Inter-
national Standards for the blood borne viruses
[13,15,17]. Studies of real-time stability are of sample AA
are ongoing.
Histograms of laboratory estimates of polymerase chain reaction (PCR)-detectable units/ml (log10) for samples AA, BB, CC and  DD (panels A, B, C and D respectively) Figure 1
Histograms of laboratory estimates of polymerase chain reaction (PCR)-detectable units/ml (log10) for sam-
ples AA, BB, CC and DD (panels A, B, C and D respectively). The laboratory code numbers are inicated in each box 
in the respective histograms.
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Discussion
The use of NAT-based assays for the detection of P. falci-
parum DNA in blood is now being increasingly used in the
management and diagnosis of malaria, particularly in
countries where travellers are returning from malaria
endemic regions. Such NAT-based assays are also being
used, on occasion in the primary screening or confirma-
tory testing of blood used for transfusion [Dr. S. Salueda,
personal communication]. In some centres performing
vaccine trials, there are reports of using DNA-based assays
to monitor parasitaemia using real-time PCR [26]. How-
ever there is widespread variation in the sensitivity and
specificity of these assays and the aim of this study was to
evaluate candidate reference preparations for P. falciparum
DNA that will be useful for standardization purposes.
The candidate standards were evaluated by a wide range of
assays from a large number of laboratories worldwide, as
is the requirement of such WHO international collabora-
tive studies [27]. During this study, the participating lab-
oratories used a variety of different extraction and
amplification methods for the detection of P. falciparum
DNA (Table 2). The majority of these assays were devel-
oped in-house and therefore it was not unsurprising to see
such a spread of results reported. The participating labora-
tories mainly returned qualitative results for the NAT-
based assays, with very few data returned for quantitative
assays. As a consequence, some variability was expected in
the range of log10 PCR-detectable units/ml, and indeed
was found to be comparable to that seen in previous stud-
ies carried out to establish other International Standard
for NAT-based assays for the blood borne viruses such as
Amplification plot of samples AA, BB, CC and DD using a TaqMan assay targeting the 18S rRNA gene of P. falciparum, as  described in Stability Section of the Materials and Methods Figure 2
Amplification plot of samples AA, BB, CC and DD using a TaqMan assay targeting the 18S rRNA gene of P. fal-
ciparum, as described in Stability Section of the Materials and Methods. The different samples are indicated on the 
figure. No template control (NTC).
 
Table 6: Stability Study – Loss relative to -20°C Sample (Log10 
drop)
Months Storage Storage Temperature
-20°C +4°C +20°C +37°C +45°C
8 0.00 -0.04 0.26 0.41 0.44
12 0.00 0.06 0.35 0.62 0.62
The accelerated thermal degradation samples were stored at +4°C, 
+20°C, +37°C and 45°C for a period of 8 and 12 months, these 
samples were compared to vials of AA that were stored continuously 
at -20°C. After 8 months, six vials of each sample stored at the 
elevated temperatures were analysed, with all sample extracts being 
tested singly. After 12 months, two vials of each sample stored at the 
elevated temperatures were analysed, with all sample extracts being 
tested duplicate. Mean values are shown for the log10 drop in titre.Malaria Journal 2008, 7:139 http://www.malariajournal.com/content/7/1/139
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HCV [13-17]. With the exclusion of outlier results, the
ranges seen in the other studies are typically between 1.5
and 2.5 log10 PCR-detectable units/ml. Whilst many of
assays targeted the 18S rRNA gene, other regions of the P.
falciparum genome were used for analysis including the
small subunit rRNA gene, the β-tubulin gene and the con-
served ATS domain of var genes (Table 2). Despite the dif-
ferences in the genes targeted by the different assays, there
is still a wide range of results, as described above, even
when the same region of the P. falciparum genome is tar-
geted, such as the multicopy 18S rRNA gene. In the case of
Laboratory 3A, results were reported for a PCR assay
directed against the 18S rRNA gene, which gave compara-
ble results to laboratory 7 targeting the single copy β-tubu-
lin gene. In a recent study [28], comparing PCR-based
detection methods for P. falciparum on a panel of field
samples from Nigeria, a range of assays based upon single
or multicopy genes gave a range, the sensitivities of which
broadly correlated with copy number, however, this is
based upon the work of a single group and not a multicen-
tre study. It would appear that even when the same genes
are targeted the difference in response observed by the
laboratories will be dependent upon the way the assays
are designed (e.g. primer and probe sequences) and
implemented (reaction mixes, buffer components, per-
formance characteristics and calibration status of thermal
cyclers etc.). The availability of an International Standard
will help to reconcile differences such as those mentioned
above.
To serve as an International Standard, ideally the prepara-
tion should be stable for many years and this is the reason
that lyophilized preparations are preferred, where residual
moisture and oxygen are minimized [27]. From the Arrhe-
nius model for accelerated degradation [24,25] the esti-
mates of the potency for the samples stored at elevated
temperatures can be used to predict the long term stability
at various temperatures. As a consequence accelerated
thermal degradation studies were carried out. In the initial
stability studies performed on the lyophilized candidate
AA, it was observed that there was very little degradation
at lower temperatures (i.e. +4°C and +20°C). There was
some observed degradation to the samples stored at
+37°C and +45°C. This may be due to natural degrada-
tion expected at these temperatures, but may also be the
result of increasing difficulty in resuspending samples
stored at elevated temperatures over time. Whilst the
results for the stability of candidate AA are not such a
good fit with the model, they nevertheless suggest that this
preparation is of adequate stability and support the long
term use of the material. Moreover, the results of the sta-
bility studies show that a short time at elevated tempera-
tures during shipment of the standard at ambient
temperatures should not cause unacceptable loss of
potency. Studies are continuing in order to monitor the
real-time stability of this material.
The discussions outlined above suggest that candidate AA
would be the most suitable to serve as the International
Standard. It also has the advantage of being based on
blood from a naturally occurring P. falciparum infection
and would therefore most closely simulate the field situa-
tion. However it should still be noted that the results for
candidate BB, based upon the P. falciparum 3D7 clone cul-
tured in leucodepleted blood, demonstrated that the
potencies of the two preparations were near identical
despite their different formulation and that results are
commutable for these two preparations. Candidate prep-
aration AA was therefore selected as the International
Standard as it demonstrated that the DNA concentration
was in a suitable range that would be acceptable for use, it
was suitable for use in a wide variety of assays utilized by
the study participants and it demonstrated good stability.
The preparation was assigned an arbitrary unitage in Inter-
national Units (IU), unrelated to the level of parasitaemia
or DNA copy number. These arbitrary units can be used to
compare assays or laboratory performance by the
response given for the International Standard.
Since the introduction of the 1st  WHO International
Standard HCV RNA International Standard ten years ago,
the number of quantitative assays available has greatly
increased. In a recent study to replace the 2nd WHO Inter-
national Standard for HCV RNA for NAT-based assays
[29] there was a marked increase in the number of quan-
titative assays and very good agreement with the determi-
nations of the potency of the current standard and the
candidate replacements. Such standards can be used for
quality control and in the determination of the analytical
sensitivity of different testing procedures. They also pro-
vide a source of material for assay validation and the pro-
duction of secondary standards to be used as run controls
or working reagents. Indeed the data generated in this
present study, produced from a large number of laborato-
ries, using a variety of different assays for P. falciparum
DNA detection, demonstrate the wide range of responses
to the panel of candidate standards and reinforce the need
for a common standard to allow inter-laboratory compar-
isons of both in-house and commercial assay sensitivities
by traceability to a "gold standard" with a physical exist-
ence.
Conclusion
In October 2006 the ECBS established this preparation as
the 1st WHO International Standard for Plasmodium falci-
parum  DNA NAT-based assays. This standard has been
assigned a unitage of 109 IU/ml. (5 × 108 IU per vial, to be
reconstituted in 0.5 ml). The 1st  WHO International
Standard for P.falciparum DNA NAT-based assays is storedPublish with BioMed Central    and   every 
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at the National Institute for Biological Standards and
Control (NIBSC code number 04/176). Details on
requesting the standard are available on the NIBSC web-
site.
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